Low-Grade Inflammation Modifies Cardiovascular Risk Even at Very Low LDL-C Levels: Are We Aiming for a Dual Target Concept?

Affiliations

¹ Deutsches Herzzentrum München, Technische Universität München, Germany. DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Germany. koenig@dhm.mhn.de.

Editorial

Wolfgang Koenig. Circulation. 2018.

. 2018 Jul 10;138(2):150-153.

doi: 10.1161/CIRCULATIONAHA.118.035107.

¹ Deutsches Herzzentrum München, Technische Universität München, Germany. DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Germany. koenig@dhm.mhn.de.

No abstract available

Keywords: C-reactive protein; Editorials; inflammation; lipoproteins, LDL; myocardial infarction; risk factors.

Comment on

Inflammatory and Cholesterol Risk in the FOURIER Trial.
Bohula EA, Giugliano RP, Leiter LA, Verma S, Park JG, Sever PS, Lira Pineda A, Honarpour N, Wang H, Murphy SA, Keech A, Pedersen TR, Sabatine MS. Bohula EA, et al. Circulation. 2018 Jul 10;138(2):131-140. doi: 10.1161/CIRCULATIONAHA.118.034032. Epub 2018 Mar 12. Circulation. 2018. PMID: 29530884 Clinical Trial.
Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy.
Pradhan AD, Aday AW, Rose LM, Ridker PM. Pradhan AD, et al. Circulation. 2018 Jul 10;138(2):141-149. doi: 10.1161/CIRCULATIONAHA.118.034645. Epub 2018 May 1. Circulation. 2018. PMID: 29716940 Free PMC article. Clinical Trial.